r/DTIC

"At a regional level, LSD increased midline cortical and motor region activity, which was associated with heightened personal relevance and meaning‐attribution to music (Preller et al. 2017), as well as enhanced tonal tracking of music in frontal, temporal, limbic, and cerebellar regions (Barrett, Preller, Herdener, et al. 2018)."

"…music listening under LSD strengthened coupling between the parahippocampus and bilateral visual cortex, as well as between visual and inferior frontal regions, reflecting enhanced emotionally driven visual‐perceptual processing (Kaelen et al. 2016)."

Bipartisan Congressional Bill Would Codify Trump’s Psychedelics Order Into Law

https://www.marijuanamoment.net/bipartisan-congressional-bill-would-codify-trumps-psychedelics-order-into-law/

H.R.9559 - To accelerate the development of, and access to, psychedelic drugs that could save lives and reverse the crisis of serious mental illness in the United States, and for other purposes. 

https://www.congress.gov/bill/119th-congress/house-bill/9559

Helps with DEA rescheduling visibility, manufacturing quotas, controlled distribution, clinical site expansion, VA-related treatment pathways, and broader institutional comfort around psychedelic medicine.

This is also the kind of policy shift that big pharma pays attention to. A late-stage drug with strong data is one thing. A late-stage drug with improving federal policy, potential priority voucher support, and clearer post-approval scheduling rules is much easier to underwrite.

Bullish for the whole sector.

Reuters story, good news https://www.reuters.com/legal/litigation/lsd-therapy-biotech-definium-fends-off-trade-secret-lawsuit-2026-07-01/

Hello everyone,

Bought 1,680 shares @ $8.30 on February 20th 2025.

Sold them all in increments of 420 shares over the last few days at an average price of $45.67.

$62,782 profit.

Good luck to everybody holding on.

I hope the price keeps going up! If it doesn't, maybe you will see me around again soon :)

This hiring slate is bullish as a launch-readiness signal, having like a company that believes DT120 has moved from “clinical asset” to “potential commercial product.”

https://job-boards.greenhouse.io/definiumtherapeutics

The jobs are not just trial-support roles. They are weighted toward pre-commercial launch infrastructure: HCP marketing, patient/digital marketing, sales leadership, product communications, MSLs, field VEOR, biostatistics/statistical programming, drug product development, and commercial supply chain. That is the exact mix you would expect when a late-stage biotech is preparing for NDA filing, label strategy, payer engagement, REMS/site-of-care planning, and possible commercial launch**.

This is not random hiring. It breaks into a very clear late-stage biotech playbook.

1. Commercial launch buildout

These roles are the loudest signal:

• Vice President, Sales
• Senior Product Manager, HCP Marketing
• Director, Patient & Digital Marketing
• Associate Director, Medical Marketing
• Director, Product Communications

That is classic pre-launch commercialization. A company does not usually build HCP marketing, patient digital, sales leadership, and product communications unless it is actively preparing the market. This does not mean approval is guaranteed, but it does mean management is preparing for the possibility that the clinical package supports filing and launch.

For DT120, this matters because the product is not a simple “ship pills to CVS” launch. It likely requires physician education, patient screening, dosing-session logistics, payer/reimbursement preparation, and potentially REMS-style controls. The Analyst Day deck already shows a support model with **field sales, medical support, access support, site-of-care support, HUB model, REMS, affordability support, benefits investigation, prior authorization support, case management, and trade/distribution.

So when you see DFTX hiring marketing, sales, communications, VEOR, MSLs, and supply chain, that lines up almost perfectly with the infrastructure shown in their commercial strategy.

2. Medical Affairs / MSL buildout

• Senior MSL - East
• Senior MSL - West

This is very important. Medical Science Liaisons are usually hired before launch to engage KOLs, educate investigators and treatment centers, handle scientific exchange, prepare congress strategy, and support evidence generation. In psychiatry — especially with a psychedelic-derived Schedule I compound — this is not optional. The field needs education.

MSLs also help bridge the gap between clinical data and real-world implementation. For DT120, they will need to explain:

DT120’s single-dose model, durability claims, safety/tolerability profile, absence of required psychotherapy in the trial design, dosing-session monitoring, potential REMS logistics, and how GAD/MDD populations were studied.

That is a strong launch-prep signal.

3. VEOR / payer strategy

• Senior Director, Field VEOR

This might be one of the most bullish roles on the list.

VEOR means **Value, Evidence, and Outcomes Research**. This is where the company builds the payer-facing case: burden of disease, treatment failures, cost offsets, claims analyses, real-world outcomes, budget impact, and formulary value proposition.

The Analyst Day deck already shows that DFTX is thinking in payer terms: 4.2 million patients failed by 2+ prescriptions, potential revenue per 1% penetration, Spravato as a reimbursement analog, payer expectations of coverage for FDA-approved psychedelic treatments, and likely prior authorization management.

Hiring Field VEOR says: they are preparing for payer conversations, not just FDA conversations.

That is usually a later-stage move.

4. Biostatistics and statistical programming

• Associate Director, Biostatistics
• Senior Director, Biostatistics
• Director, Statistical Programming

This is approval-path infrastructure. These are the people needed for Phase 3 readouts, integrated safety/efficacy analyses, FDA questions, NDA datasets, tables/listings/figures, subgroup analyses, label discussions, and post-hoc/pooled analyses.

For a company with multiple Phase 3 studies reading out close together, this is critical. DFTX’s decks show Emerge, Voyage, Panorama, Ascend, and future PTSD/Haven planning. They also emphasize SSRE, powering assumptions, minimum detectable differences, and integrated Phase 3 design logic.

This hiring tells me they are preparing for a heavy data package and possible regulatory submission work.

5. CMC / drug product / supply chain

• Associate Director, Drug Product Development
• Executive Director, Commercial Supply Chain

This is another major signal.

For DT120, commercial supply chain is not trivial. The asset is lysergide tartrate, a controlled substance. The company would need manufacturing, quality systems, controlled-substance handling, packaging, distribution, inventory controls, and potentially REMS-aligned logistics.

A commercial supply chain executive is not usually a “maybe someday” hire. It is a “we need to be ready if/when the product gets approved” hire.

This is especially relevant because DFTX is trying to create a scalable episodic-care model: single oral dose, 5–8 hour monitoring, end-of-session checklist, next-day return to normal activities, and treatment-site workflow. The May deck lays out that target product profile directly.

6. Clinical development and program management

• Associate Director, Clinical Development
• Senior Director, Clinical Development
• Senior Project Manager

This supports ongoing trials, label expansion, extension studies, additional indications, FDA interactions, site oversight, and cross-functional execution. This is not as directly “commercial” as VP Sales or Field VEOR, but it supports the broader DT120 lifecycle.

The decks show DT120 is not just one trial in one indication. It is a platform-like clinical program across GAD, MDD, PTSD, and possible additional indications.

The biotech late-stage hiring playbook

A late-stage biotech usually evolves in stages:

Stage 1: Clinical proof-of-concept company

Mostly R&D, clinical operations, regulatory, CMC, finance. Commercial is small or nonexistent.

Stage 2: Pivotal-readout company

Adds biostatistics, statistical programming, regulatory ops, medical affairs planning, publication planning, market research, HEOR/VEOR, and early brand strategy.

Stage 3: Pre-NDA / pre-launch company

Adds HCP marketing, patient marketing, product communications, sales leadership, market access, field medical, commercial analytics, supply chain, patient services, HUB planning, distribution, and REMS planning.

Stage 4: Launch company

Adds field sales managers, reps, access/reimbursement teams, nurse educators/site support, patient services, pharmacovigilance expansion, trade/distribution, compliance, training, sales ops, and full medical affairs coverage.

DFTX’s job list looks like Stage 3. They are not merely keeping trials alive. They are building the bridge from Phase 3 data to market entry.

Simple - does anyone have a better date for Voyage then "some time in July" ?

More complicated - as someone with a delightful amount of exposure, I'm considering some Puts to give myself a safe landing no matter what. Anyone else considering that or have thoughts?

Are you ALL eating GOOD TONIGHT???

Let's go!